Celyad SA (CYAD) vs TScan Therapeutics, Inc. (TCRX)

Celyad SA and TScan Therapeutics, Inc. are both Biotechnology companies. Celyad SA and TScan Therapeutics, Inc. are of similar size ($23.8M and $23.7M). Celyad SA has the higher net margin (0.00% vs −1,655.4%) and the higher return on invested capital (0.00% vs −4,588.2%). Across the 14 metrics below, Celyad SA leads on 8 and TScan Therapeutics, Inc. on 6.

Valuation

Metric CYAD TCRX Biotechnology median
P/E n/m n/m 7.88
P/S n/m 6.21 11.47
P/B 11.18 0.64 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.20 0.74
EV/Sales n/m (3.26) 10.73
Earnings yield (708.87%) (267.65%) (28.84%)
Free cash flow yield (438.06%) (268.00%) (23.03%)

Profitability

Metric CYAD TCRX Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin — (1,695.15%) 0.00%
Net margin 0.00% (1,655.35%) 0.00%
Free cash flow margin 0.00% (1,665.18%) 0.00%
Return on equity 0.00% (95.80%) (57.72%)
Return on assets 0.00% (50.09%) (49.22%)
Return on invested capital 0.00% (4,588.23%) 0.00%

Growth

Metric CYAD TCRX Biotechnology median
Revenue growth (TTM) — 2.15% 5.64%
EPS growth (last fiscal year) 113.33% 12.28% —
Revenue growth, 5-year CAGR (63.51%) 56.92% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CYAD TCRX Biotechnology median
Debt to equity (0.24) 0.47 0.00
Current ratio 0.66 3.37 4.73
Net debt to EBITDA (1.62) 0.90 0.96

Dividend

Metric CYAD TCRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CYAD TCRX Biotechnology median
Market cap 23.79m 23.65m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack